Balaxi Pharmaceuticals Ltd
BALAXI
Company Profile
Business description
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. Geographically it earns key revenue from Guatemala.
Contact
Phase-III, Road No: 81, Jubilee Hills
Plot No.409, H,No: 8-2-293
MAPS Towers, 3rd Floor
HyderabadTG500 096
INDT: +91 4023555300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
46
Stocks News & Analysis
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,470.20 | 1.60 | -0.02% |
| CAC 40 | 7,423.67 | 15.03 | 0.20% |
| DAX 40 | 20,271.33 | 138.48 | 0.69% |
| Dow JONES (US) | 42,518.28 | 221.16 | 0.52% |
| FTSE 100 | 8,201.54 | 22.65 | -0.28% |
| HKSE | 19,256.77 | 36.99 | 0.19% |
| NASDAQ | 19,044.39 | 43.71 | -0.23% |
| Nikkei 225 | 38,576.66 | 102.36 | 0.27% |
| NZX 50 Index | 12,946.00 | 61.62 | 0.48% |
| S&P 500 | 5,842.91 | 6.69 | 0.11% |
| S&P/ASX 200 | 8,225.90 | 5.10 | -0.06% |
| SSE Composite Index | 3,232.96 | 7.98 | -0.25% |